Conor Steuer

Department of Hematology and Medical Oncology
Associate Professor

(404) 727-5658
csteuer@emory.edu

Academic Appointment

Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MD from New York University, New York
BA from Johns Hopkins University, Baltimore

Research

Publications

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Nat Med Volume: 29 Page(s): 880 - 887
04/01/2023 Authors: Saba NF; Steuer CE; Ekpenyong A; McCook-Veal A; Magliocca K; Patel M; Schmitt NC; Stokes W; Bates JE; Rudra S
T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.
J Immunother Cancer Volume: 10
06/01/2022 Authors: Wang X; Muzaffar J; Kirtane K; Song F; Johnson M; Schell MJ; Li J; Yoder SJ; Conejo-Garcia JR; Guevara-Patino JA
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res Volume: 28 Page(s): 2329 - 2338
06/01/2022 Authors: Chung CH; Li J; Steuer CE; Bhateja P; Johnson M; Masannat J; Poole MI; Song F; Hernandez-Prera JC; Molina H
A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
Cancers (Basel) Volume: 14
05/26/2022 Authors: Bauman JE; Chen Z; Zhang C; Ohr JP; Ferris RL; McGorisk GM; Brandt S; Srivatsa S; Chen AY; Steuer CE
Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.
Oncologist Volume: 27 Page(s): 48 - 56
02/03/2022 Authors: Vijayvargiya P; Trivedi S; Rupji M; Song H; Liu Y; Jiang R; Kaka AS; Chen GZ; Stokes W; Steuer C
The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: No local-regional failures.
Head Neck Volume: 44 Page(s): 382 - 390
02/01/2022 Authors: Dhere VR; Escott CE; Tian S; Switchenko JM; Bell JP; Stokes WA; McDonald MW; Magliocca KR; Boyce BJ; Kaka AS
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.
Cancer Discov Volume: 12 Page(s): 74 - 89
01/01/2022 Authors: Jnne PA; Baik C; Su W-C; Johnson ML; Hayashi H; Nishio M; Kim D-W; Koczywas M; Gold KA; Steuer CE
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Oncologist Volume: 26 Page(s): 925 - e1918
11/01/2021 Authors: Do KT; Chow LQM; Reckamp K; Sanborn RE; Burris H; Robert F; Camidge DR; Steuer CE; Strickler JH; Weise A
Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer.
JCO Oncol Pract Volume: 17 Page(s): 662 - 668
11/01/2021 Authors: Steuer CE; Ramalingam SS
Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016.
Cancer Med Volume: 10 Page(s): 6070 - 6077
09/01/2021 Authors: Taylor MA; Switchenko J; Stokes W; Patel MR; McDonald M; Steuer C; Aiken A; Beitler JJ; Shin DM; Saba NF
Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
Volume: 32 Page(s): S318 - S318
07/26/2021 Authors: Hayashi H; Yu HA; Baik C; Gold K; Johnson ML; Koczywas M; Murakami H; Nishio M; Steuer C; Su W-C
Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus.
Radiother Oncol Volume: 160 Page(s): 140 - 147
07/01/2021 Authors: Carsuzaa F; Lapeyre M; Gregoire V; Maingon P; Beddok A; Marcy P-Y; Salleron J; Coutte A; Racadot S; Pointreau Y
TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.
Oral Oncol Volume: 117 Page(s): 105294
06/01/2021 Authors: Patel MR; Ottenstein L; Ryan M; Farrell A; Studer M; Baddour HM; Magliocca K; Griffith C; Stokes W; Switchenko J
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
J Thorac Oncol Volume: 16 Page(s): 960 - 967
06/01/2021 Authors: Steuer CE; Jegede OA; Dahlberg SE; Wakelee HA; Keller SM; Tester WJ; Gandara DR; Graziano SL; Adjei AA; Butts CA
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.
Cancers (Basel) Volume: 13
03/09/2021 Authors: Chung CH; Bonomi M; Steuer CE; Li J; Bhateja P; Johnson M; Masannat J; Song F; Hernandez-Prera JC; Wenig BM
An update on the immune landscape in lung and head and neck cancers (vol 70, pg 505, 2020)
CA-A CANCER JOURNAL FOR CLINICIANS Volume: 71 Page(s): 280 - 280
03/08/2021 Authors: Carlisle JW; Steuer CE; Owonikoko TK; Saba NF
Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
Volume: 16 Page(s): S107 - S107
03/01/2021 Authors: Yu H; Baik C; Gold K; Hayashi H; Johnson M; Koczywas M; Murakami H; Nishio M; Steuer C; Su W
Radiotherapy with Concurrent Versus Sequential Osimertinib for Advanced Non-Small Cell Lung Cancer: a Multi-Center Toxicity Analysis
Volume: 16 Page(s): S586 - S587
03/01/2021 Authors: Qian D; Behera M; Carlisle J; Owonikoko T; Steuer C; Pakkala S; Kesarwala A; Fischer-Valuck B; Bradley J; Curran W
Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma.
JCO Oncol Pract Volume: 17 Page(s): e313 - e322
03/01/2021 Authors: Marks JA; Switchenko JM; Steuer CE; Ryan M; Patel MR; McDonald MW; Higgins K; Beitler JJ; Shin DM; Gillespie TW
Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
Laryngoscope Volume: 131 Page(s): E921 - E928
03/01/2021 Authors: Tkaczuk A; Trivedi S; Mody MD; Steuer CE; Shin DM; Klein AM; Saba NF
Surgical Resection is Justifiable for Oral T4b Squamous Cell Cancers With Masticator Space Invasion.
Laryngoscope Volume: 131 Page(s): E466 - E472
02/01/2021 Authors: Baddour HM; Ochsner MC; Patel MR; Switchenko JM; Beitler JJ; Magliocca K; Baugnon KL; Solares CA; Steuer CE; El-Deiry MW
Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.
Oral Oncol Volume: 112 Page(s): 105074
01/01/2021 Authors: Wang D; Lu Y; Nannapaneni S; Griffith CC; Steuer C; Qian G; Wang X; Chen Z; Patel M; El-Deiry M
Outcomes and Predictive Value of Post-adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma.
Laryngoscope Volume: 130 Page(s): E850 - E857
12/01/2020 Authors: Qian DC; Magliocca KR; Aiken AH; Baugnon KL; Brandon DC; Stokes WA; McDonald MW; Patel MR; Baddour HM; Kaka AS
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
J Immunother Cancer Volume: 8
12/01/2020 Authors: Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
Clin Cancer Res Volume: 26 Page(s): 5860 - 5868
11/15/2020 Authors: Shin DM; Nannapaneni S; Patel MR; Shi Q; Liu Y; Chen Z; Chen AY; El-Deiry MW; Beitler JJ; Steuer CE
An update on the immune landscape in lung and head and neck cancers.
CA Cancer J Clin Volume: 70 Page(s): 505 - 517
11/01/2020 Authors: Carlisle JW; Steuer CE; Owonikoko TK; Saba NF
Impact of Postoperative Radiation Therapy Timing on Survival in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Volume: 108 Page(s): E805 - E805
11/01/2020 Authors: Tian S; Switchenko J; Patel MR; Saba NF; Shin DM; Steuer C; Dhere VR; McDonald MW; Higgins KA; Beitler JJ
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
Transl Lung Cancer Res Volume: 9 Page(s): 1720 - 1723
10/01/2020 Authors: Steuer CE; Ramalingam SS
Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
Int J Radiat Oncol Biol Phys Volume: 108 Page(s): 304 - 313
09/01/2020 Authors: Tian S; Switchenko JM; Buchwald ZS; Patel PR; Shelton JW; Kahn SE; Pillai RN; Steuer CE; Owonikoko TK; Behera M
COMPARISON OF THE 7TH AND 8TH EDITIONS OF THE AMERICAN JOINT COMMITTEE ON CANCER (AJCC) STAGING FOR OROPHARYNGEAL SQUAMOUS CELL CARCINOMAS (OPSCC): A SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS PROGRAM (SEER) DATABASE ANALYSIS
Volume: 35 Page(s): S72 - S72
07/01/2020 Authors: Vijayvargiya P; Trivedi S; Song H; Liu Y; Steuer C; Stokes W; Kaka A; Patel M; Chen G; Shin D
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA
Demographic and Socioeconomic Factors Associated With Metastases at Presentation in HPV-Related Squamous Cell Carcinoma of the Head and Neck: An NCDB Analysis.
JCO Oncol Pract Volume: 16 Page(s): e476 - e487
06/01/2020 Authors: Bean MB; Switchenko JM; Steuer CE; Patel M; Higgins K; McDonald M; Chen GZ; Beitler JJ; Shin DM; Gillespie T
Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors
Volume: 26 Page(s): 37 - 37
06/01/2020 Authors: Evans EE; Lesinski GB; Fisher TL; Mallow C; Olson B; Clavijo PE; Leonard JE; Pastore DR; Smith ES; Zauderer M
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
Oncologist Volume: 25 Page(s): e964 - e975
06/01/2020 Authors: Behera M; Steuer CE; Liu Y; Fernandez F; Fu C; Higgins KA; Gillespie TW; Pakkala S; Pillai RN; Force S
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
Volume: 38
05/20/2020 Authors: Chung CH; Bonomi MR; Steuer CE; Schell MJ; Li J; Johnson M; Masannat J; Hernandez-Prera JC; McMullen C; Wadsworth J
KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer.
Volume: 38
05/20/2020 Authors: Qian D; Behera M; Steuer CE; Pakkala S; Carlisle JW; Owonikoko TK; Fischer-Valuck BW; Kesarwala AH; Bradley J; Curran WJ
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Volume: 38
05/20/2020 Authors: Bauman JE; Roe D; Saba NF; Bauman JR; Kaczmar JM; Burtness B; Muzaffar J; Julian RA; Wang S; Bearelly S
Comparison of the 7th and 8th editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis
Volume: 106 Page(s): 1200 - 1201
04/01/2020 Authors: Vijayvargiya P; Trivedi S; Song H; Liu Y; Steuer C; Stokes WA; Kaka AS; Patel MR; Chen G; Shin DM
Surgical Resection is Justifiable for Oral T4b Squamous Cell Cancers with Masticator Space Invasion
Volume: 106 Page(s): 1156 - 1156
04/01/2020 Authors: Baddour HM; Ochsner M; Patel MR; Switchenko J; Beitler JJ; Magliocca KR; Solares CA; Steuer C; Baugnon KL; El-Deiry MW
Outcomes and Predictive Value of Post-Adjuvant Therapy Surveillance PET/CECT for Locally Advanced Oral Squamous Cell Carcinoma
Volume: 106 Page(s): 1180 - 1180
04/01/2020 Authors: Qian DC; Magliocca KR; Aiken AH; Baugnon KL; Brandon DC; Stokes WA; McDonald MW; Patel MR; Baddour HM; Kaka AS
Integrated Biomarker Study of Pepinemab in Combination with Nivolumab or Ipilimumab to Evaluate Immune Cell Composition of TME in Patients with Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Volume: 106 Page(s): 1175 - 1175
04/01/2020 Authors: Steuer C; Lesinski GB; Evans EE; Fisher TL; Mallow C; Olson B; Pastore DR; Leonard JE; Smith E; Zauderer M
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist Volume: 25 Page(s): e528 - e535
03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Lancet Oncol Volume: 21 Page(s): 271 - 282
02/01/2020 Authors: Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Cancer Volume: 126 Page(s): 575 - 582
02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT
Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
PLoS One Volume: 15 Page(s): e0238497
01/01/2020 Authors: Saba NF; Dinasarapu AR; Magliocca KR; Dwivedi B; Seby S; Qin ZS; Patel M; Griffith CC; Wang X; El-Deiry M
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist
12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H
Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data.
Oncologist Volume: 24 Page(s): 1562 - 1569
12/01/2019 Authors: Bean MB; Liu Y; Jiang R; Steuer CE; Patel M; McDonald MW; Higgins KA; Beitler JJ; Shin DM; Saba NF
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Invest New Drugs Volume: 37 Page(s): 1198 - 1206
12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study
Volume: 7
11/06/2019 Authors: Chung C; Bonomi M; Steuer C; Schell M; Li J; Johnson M; McMullen C; Wadsworth JT; Patel K; Kish J
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: APropensity Score-Matched Analysis of the National Cancer Database.
Clin Lung Cancer Volume: 20 Page(s): 484 - 493.e6
11/01/2019 Authors: Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
Lung Stereotactic Body Radiotherapy and Concurrent Immunotherapy: A Multi-Center Safety and Toxicity Analysis
Volume: 14 Page(s): S248 - S248
10/01/2019 Authors: Tian S; Switchenko J; Patel P; Shelton J; Kahn S; Pillai R; Steuer C; Owonikoko T; Behera M; Curran W
Integration of Durvalumab into the Treatment of Stage III Non-Small Cell Lung Cancer: Real-World Considerations
Volume: 14 Page(s): S588 - S589
10/01/2019 Authors: Gorgens S; Schreibmann E; Behera M; Steuer C; Pillai R; Owonikoko T; Shelton J; Ramalingam S; Curran W; Higgins K
Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Volume: 30
10/01/2019 Authors: Trivedi S; Steuer CE; Tkaczuk AT; Shin DM; Klein A; Saba NF
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Lancet Oncol Volume: 20 Page(s): 1295 - 1305
09/01/2019 Authors: Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
BMC Cancer Volume: 19 Page(s): 857
08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL
Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Volume: 79
07/01/2019 Authors: Lesinski GB; Fisher TL; Evans EE; Leonard JE; Pastore DR; Mallow C; Smith E; Zauderer M; Steuer C; Saba NF
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Lung Cancer Volume: 133 Page(s): 96 - 102
07/01/2019 Authors: Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou S-HI; Costa DB; Gadgeel SM
Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis.
Volume: 37
05/20/2019 Authors: Trivedi S; Song H; Liu Y; Steuer CE; Stokes W; Kaka A; Patel M; Chen ZG; Shin DM; Aiken A
Socioeconomic contributions to clinical outcome by HPV status in squamous cell carcinomas of the head and neck (SCCHN):An analysis of NCDB.
Volume: 37
05/20/2019 Authors: Marks JA; Switchenko JM; Steuer CE; Herrin S; Ryan MA; Patel M; El-Deiry M; Beitler JJ; Shin DM; Gillespie TW
Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.
Volume: 37
05/20/2019 Authors: Shin DM; Beitler JJ; El-Deiry M; Steuer CE; Chen AY; Baddour HM; Chen ZG; Roser S; Magliocca KR; Patel M
Factors associated with metastatic presentation in HPV-related squamous cell carcinoma of the head and neck (SCCHN): A National Cancer Database (NCDB) analysis.
Volume: 37
05/20/2019 Authors: Bean MB; Switchenko JM; Steuer CE; Patel M; El-Deiry M; Higgins KA; McDonald MW; Chen ZG; Beitler JJ; Shin DM
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
Volume: 37
05/20/2019 Authors: Owonikoko TK; Higgins KA; Chen Z; Zhang C; Pillai RN; Steuer CE; Saba NF; Pakkala S; Shin DM; Zhang G
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Volume: 41 Page(s): 1490 - 1498
05/01/2019 Authors: Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R
Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx.
Cancer Volume: 125 Page(s): 704 - 711
03/01/2019 Authors: Beitler JJ; Switchenko JM; Dignam JJ; McDonald MW; Saba NF; Shin DM; Magliocca KR; Cassidy RJ; El-Deiry MW; Patel MR
Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
Volume: 7
02/01/2019 Authors: Bilen M; Martini D; Liu Y; Lewis C; Collins H; Shabto J; Akce M; Kissick H; Carthon B; Shaib W
Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas.
Laryngoscope Volume: 129 Page(s): 377 - 386
02/01/2019 Authors: Cassidy RJ; Switchenko JM; El-Deiry MW; Belcher RH; Zhong J; Steuer CE; Saba NF; McDonald MW; Yu DS; Gillespie TW
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Cancer Volume: 125 Page(s): 127 - 134
01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL
Why Immunotherapy Will Become the New Standard of Care in HNSCC
ONCOLOGY-NEW YORK Volume: 32 Page(s): 618 - 618
12/01/2018 Authors: Steuer C
Medulla Dose is Positively Associated with Sensation of Thirst & Midbrain Dose is Inversely Associated with Pain: Prospectively-Collected Patient-Reported Toxicities and Brainstem Dose in Head and Neck Cancer Radiation Therapy
Volume: 102 Page(s): E198 - E198
11/01/2018 Authors: Ferris MJ; Switchenko J; Xiao C; McDonald MW; Eaton BR; Higgins KA; Press RH; Tian S; Steuer C; Baddour HM
Report of Neurotoxicity after Concurrent Whole Brain Radiation Therapy and Checkpoint Blockade Immunotherapy for Patients with Brain Metastases
Volume: 102 Page(s): E340 - E340
11/01/2018 Authors: Press RH; Buchwald ZS; Steuer C; Pillai R; Owonikoko TK; Ramalingam S; Curran WJ; Higgins KA
Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Ann Oncol Volume: 29 Suppl 8 Page(s): viii433
10/01/2018 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins HH; Akce M; Kissick H; Carthon BC; Shaib WL
Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
Volume: 13 Page(s): S815 - S816
10/01/2018 Authors: Janne P; Yu H; Johnson M; Steuer C; Vigliotti M; Shipitofsky N; Guevara FM; Chen S; Yu C
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Cancer Volume: 124 Page(s): 3586 - 3595
09/01/2018 Authors: Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Cancer Cell Volume: 34 Page(s): 315 - 330.e7
08/13/2018 Authors: Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang H-B; Song L; Wang D
Effective reduction of PD-L1 expression by simultaneous blockade of EGFR and HER3 (ErbB3) in head and neck cancer
Volume: 78
07/01/2018 Authors: Chen ZG; Wang D; Griffith CC; Nannapaneni S; Steuer C; Patel MR; El-Deiry MW; Wang X; Zhang Y; Chen Z
Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
Volume: 78
07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R
Racial disparities in surgical management and survival in hispanic patients with potentially resectable esophageal cancer.
Volume: 36
05/20/2018 Authors: Gupta D; Liu Y; Jiang R; Fernandez F; Force S; Pickens A; Steuer CE; McDonald MW; Higgins KA; Beitler JJ
Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
Volume: 36
05/20/2018 Authors: Martini DJ; Liu Y; Lewis CM; Shabto JM; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai RN
The Effect of Hospital Volume and Insurance Status on Overall Survival in Sinonasal Carcinoma: A National Cancer Database (NCDB) Analysis
Volume: 100 Page(s): 1385 - 1386
04/01/2018 Authors: Trivedi S; Switchenko J; Patel MR; Steuer C; El-Deiry MW; Higgins KA; Solares CA; McDonald MW; Shin DM; Gillespie T
Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas
Volume: 100 Page(s): 1382 - 1382
04/01/2018 Authors: Cassidy RJ; Switchenko J; El-Deiry MW; Belcher RH; Zhong J; Steuer C; Saba NF; McDonald MW; Yu DS; Gillespie T
A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
Mol Cancer Ther Volume: 17 Page(s): 710 - 716
03/01/2018 Authors: Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
J Clin Oncol Volume: 36 Page(s): 631 - 632
03/01/2018 Authors: Steuer CE; Ramalingam SS
Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
Cancer Volume: 124 Page(s): 775 - 784
02/15/2018 Authors: Cassidy RJ; Zhang X; Switchenko JM; Patel PR; Shelton JW; Tian S; Nanda RH; Steuer CE; Pillai RN; Owonikoko TK
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
Ann Oncol Volume: 29 Page(s): i20 - i27
01/01/2018 Authors: Remon J; Steuer CE; Ramalingam SS; Felip E
Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.
Radiother Oncol Volume: 126 Page(s): 100 - 106
01/01/2018 Authors: Ferris MJ; Zhong J; Switchenko JM; Higgins KA; Cassidy RJ; McDonald MW; Eaton BR; Patel KR; Steuer CE; Baddour HM
Malignant Mesothelioma: An Unexpected Diagnosis in a Young Man
Volume: 197
01/01/2018 Authors: Kang M; Khullar OV; Steuer C; Van Nostrand K
Health care disparities among octogenarians and nonagenarians with stage II and III rectal cancer.
Cancer Volume: 123 Page(s): 4325 - 4336
11/15/2017 Authors: Cassidy RJ; Switchenko JM; Cheng E; Jiang R; Jhaveri J; Patel KR; Tanenbaum DG; Russell MC; Steuer CE; Gillespie TW
Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
Clin Lung Cancer Volume: 18 Page(s): 706 - 718
11/01/2017 Authors: Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
J Thorac Oncol Volume: 12 Page(s): 1687 - 1695
11/01/2017 Authors: Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
J Natl Cancer Inst Volume: 109
11/01/2017 Authors: Goldstein DA; Gordon N; Davidescu M; Leshno M; Steuer CE; Patel N; Stemmer SM; Zer A
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study
Volume: 12 Page(s): S2013 - S2014
11/01/2017 Authors: Higgins K; Pillai R; Chen Z; Zhang C; Patel P; Pakkala S; Shelton J; Force S; Fernandez F; Steuer C
Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cancer Volume: 123 Page(s): 3681 - 3690
10/01/2017 Authors: Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN
Next Generation Sequencing and Clinical Outcomes of Lung Adenocarcinomas Treated With Stereotactic Body Radiation Therapy
Volume: 99 Page(s): S241 - S241
10/01/2017 Authors: Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer C; Pillai R
KRAS Mutant Non-small Cell Lung Cancer is Associated With Increased Risk of Salvage Whole Brain Radiation after Stereotactic Radiosurgery for Brain Metastases
Volume: 99 Page(s): E100 - E101
10/01/2017 Authors: Press RH; Zhang X; Cassidy RJ; Ferris MJ; Zhong J; Steuer C; Pillai R; Owonikoko TK; Ramalingam S; Patel PR
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Cancer Volume: 123 Page(s): 3476 - 3485
09/15/2017 Authors: Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
JAMA Oncol Volume: 3 Page(s): 1120 - 1129
08/01/2017 Authors: Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ
Institutional treatment volume and outcomes in salivary gland cancer.
Volume: 35
05/20/2017 Authors: Steuer CE; Switchenko JM; Griffith CC; Patel M; Cassidy RJ; Gillespie TW; McDonald MW; Higgins KA; Beitler JJ; Owonikoko TK
Small cell carcinoma of the head and neck: Incidence and survival trends based on the Surveillance and Epidemiologic and End Results (SEER) analysis.
Volume: 35
05/20/2017 Authors: Bean M; Goodman M; Steuer CE; Patel M; McDonald MW; Higgins KA; Owonikoko TK; Beitler JJ; Shin DM; Saba NF
Enrollment into molecular selection trials and impact on patient disposition.
Volume: 35
05/20/2017 Authors: Harvey RD; Steuer CE; Judson EC; Lewis CM; Collins HH; Saba NF; El-Rayes BF; Curran WJ; Rannalingam SS; Pentz RD
Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.
Volume: 35
05/20/2017 Authors: Higgins KA; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
Optimal thoracic radiation dose in limited stage small cell lung cancer.
Volume: 35
05/20/2017 Authors: Behera M; Zhang X; Jiang R; Pillai RN; Patel PR; Pakkala S; Steuer CE; Saba NF; Owonikoko TK; Belani C
A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.
Volume: 35
05/20/2017 Authors: Goldstein DA; Gordon N; Davidescu M; Leshno M; Steuer CE; Patel N; Stemmer SM; Zer A
Presence of genetic aberrations in patients with brain metastases from non-small cell lung cancer (NSCLC) and clinical outcomes
Volume: 35
05/20/2017 Authors: Press RH; Zhang X; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Ramalingam SS; Patel PR
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
Volume: 18 Page(s): 286 - 292
05/01/2017 Authors: Steuer CE; Behera M; Liu Y; Fu C; Gillespie TW; Saba NF; Shin DM; Pillai RN; Pakkala S; Owonikoko TK
Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
Cancer Volume: 123 Page(s): 783 - 793
03/01/2017 Authors: Cassidy RJ; Liu Y; Patel K; Zhong J; Steuer CE; Kooby DA; Russell MC; Gillespie TW; Landry JC
The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.
Annu Rev Med Volume: 68 Page(s): 153 - 168
01/14/2017 Authors: Ernani V; Steuer CE; Jahanzeb M
Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
Volume: 12 Page(s): S470 - S470
01/01/2017 Authors: Behera M; Gillespie T; Liu Y; Jia Y; Higgins K; Steuer C; Saba N; Shin D; Pakkala S; Pillai R
Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer
Volume: 12 Page(s): S855 - S856
01/01/2017 Authors: Ahmed H; Liu Y; O'Conne K; Gillespie T; Ahmed M; Pate P; Pillai R; Behera M; Steuer C; Owonikoko T
Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis
Volume: 12 Page(s): S703 - S704
01/01/2017 Authors: Kim S; Ragin C; Chen Z; Behera M; Pillai R; Steuer C; Belani C; Khuri F; Ramalingam S; Owonikoko T
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor.
Oncology Volume: 93 Page(s): 336 - 342
01/01/2017 Authors: Evans M; Liu Y; Chen C; Steuer C; Cassidy R; Landry J; Higgins K; Beitler JJ; Willingham F; Owonikoko TK
An update on larynx cancer.
CA Cancer J Clin Volume: 67 Page(s): 31 - 50
01/01/2017 Authors: Steuer CE; El-Deiry M; Parks JR; Higgins KA; Saba NF
Regarding BRAF-inhibitor therapy of primary ameloblastoma.
Oral Surg Oral Med Oral Pathol Oral Radiol Volume: 122 Page(s): 517 - 518
10/01/2016 Authors: Magliocca KR; Steuer CE; Hudgins PA; Bouloux GF
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma.
Volume: 17 Page(s): e57 - e64
09/01/2016 Authors: Behera M; Owonikoko TK; Gal AA; Steuer CE; Kim S; Pillai RN; Khuri FR; Ramalingam SS; Sica GL
An integrated workflow to identify targetable mutations in FFPE samples of HNSCC.
Volume: 34
05/20/2016 Authors: Saba NF; Magliocca KR; Patel M; Steuer CE; Newman S; Zhang H; El-Deiry M; Wadsworth JT; Kowalski J; Shin DM
A correlative analysis of PDL-1, PD-1, and EGFR, HER2, HER3 expression in oropharyngeal squamous cell carcinoma (OPSCC).
Volume: 34
05/20/2016 Authors: Steuer CE; Griffith CC; Liu Y; Magliocca KR; Patel M; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF
Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).
Volume: 34
05/20/2016 Authors: Behera M; Gillespie TW; Liu Y; Jia Y; Higgins KA; Steuer CE; Saba NF; Shin DM; Pakkala S; Pillai RN
Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base
Volume: 34
05/20/2016 Authors: Naik K; Liu Y; Goodman M; Gillespie TW; El-Rayes BF; Pickens A; Force S; Steuer CE; Owonikoko TK; Ramalingam SS
Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.
Volume: 34
05/20/2016 Authors: Evans M; Liu Y; Chen C; Gillespie TW; Steuer CE; Owonikoko TK; Ramalingam SS; Beitler JJ; El-Rayes BF; Fernandez F
Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
Support Care Cancer Volume: 24 Page(s): 1789 - 1793
04/01/2016 Authors: McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Cancer Volume: 122 Page(s): 766 - 772
03/01/2016 Authors: Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA
Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
Cancer Volume: 122 Page(s): 50 - 60
01/01/2016 Authors: Behera M; Ragin C; Kim S; Pillai RN; Chen Z; Steuer CE; Saba NF; Belani CP; Khuri FR; Ramalingam SS
Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy.
Front Oncol Volume: 6 Page(s): 272
01/01/2016 Authors: Sayan M; Cassidy RJ; Switchenko JM; Kayode OA; Saba NF; Steuer CE; Shin DM; Wadsworth JT; El-Deiry M; Patel M
Targeting EGFR in lung cancer: Lessons learned and future perspectives.
Mol Aspects Med Volume: 45 Page(s): 67 - 73
11/01/2015 Authors: Steuer CE; Ramalingam SS
Squamous Cell Carcinoma of Lung in the United States: Analysis of the National Cancer Database (NCDB)
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S367 - S367
09/01/2015 Authors: Behera M; Owonikoko TK; Liu Y; Gillespie TW; Yuan M; Pillai RN; Steuer C; Higgins KA; Pakkala S; Belani CP
A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide Concurrent with Thoracic Radiation for Stage III NSCLC Patients
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S212 - S212
09/01/2015 Authors: Steuer C; Behera M; Higgins KA; Saba N; Shin D; Pakkala S; Pillai R; Owonikoko TK; Curran WJ; Belani CP
Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S545 - S545
09/01/2015 Authors: Kumar M; Ragin C; Zhang C; Chen Z; Han EJ; Ernani V; Behera M; Steuer C; Saba N; Shin D
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
J Thorac Oncol Volume: 10 Page(s): 1142 - 1147
08/01/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
Investigating the correlation between disease burden and symptoms in patients with advanced stage lung cancer.
Volume: 33
05/20/2015 Authors: Geiger C; Chen Z; Zhang C; Behera M; Steuer CE; Pillai RN; Ramalingam SS
Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes.
Volume: 33
05/20/2015 Authors: Owonikoko TK; Nelson M; Park SY; Kim S; Steuer CE; Behera M; Chen Z; Han E; Kumar M; Ernani V
Pemetrexed versus taxane-containing platinum doublet therapy for advanced non-squamous non-small cell lung cancer (NSCLC): A systematic analysis.
Volume: 33
05/20/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Pakkala S; Steuer CE; Saba NF; Shin DM; Belani CP; Khuri FR; Ramalingam SS
Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database.
Volume: 33
05/20/2015 Authors: Behera M; Steuer CE; Fernandez F; Liu Y; Fu C; Gillespie TW; Higgins KA; Saba NF; Pillai RN; Force S
Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data
Volume: 33
05/20/2015 Authors: Saba NF; Newman S; Rossi MR; Steuer CE; Zhang H; Patel M; Wadsworth JT; El-Deiry M; Magliocca KR; Owonikoko TK
Innovative Clinical Trials: The LUNG-MAP Study.
Clin Pharmacol Ther Volume: 97 Page(s): 488 - 491
05/01/2015 Authors: Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.
Cancer Volume: 121 Page(s): E1 - E6
04/15/2015 Authors: Steuer CE; Khuri FR; Ramalingam SS
Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis.
Lung Cancer Volume: 88 Page(s): 80 - 84
04/01/2015 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai R; Saba NF; Shin DM; Owonikoko TK; Khuri FR
Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis.
J Thorac Oncol Volume: 10 Page(s): 479 - 485
03/01/2015 Authors: Steuer CE; Behera M; Kim S; Chen Z; Saba NF; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
Investigating the Molecular Profile of Lung Adenocarcinoma: A Single-Institution Analysis
Volume: 90 Page(s): S50 - S51
11/15/2014 Authors: Steuer C; Behera M; Rossi M; Fisher K; Sica G; Gal A; Pakkala S; Pillai R; Owonikoko T; Khuri F
Evaluation of Hospitalization Trends in Lung Cancer Patients With Hyponatremia
Volume: 90 Page(s): S62 - S62
11/15/2014 Authors: Kazi HA; Behera M; Steuer C; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
Volume: 90 Page(s): S68 - S69
11/15/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS
EVALUATION OF HOSPITALIZATION TRENDS IN LUNG CANCER PATIENTS WITH HYPONATREMIA
JOURNAL OF THORACIC ONCOLOGY Volume: 9 Page(s): S182 - S182
09/01/2014 Authors: Kazi HA; Behera M; Steuer C; Owonikoko T; Pillai R; Ramalingam SS; Khuri FR
A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
Volume: 90 Page(s): S80 - S81
09/01/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS
ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options.
Cancer Volume: 120 Page(s): 2392 - 2402
08/15/2014 Authors: Steuer CE; Ramalingam SS
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant Volume: 20 Page(s): 852 - 857
06/01/2014 Authors: Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S
Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis
Volume: 32
05/20/2014 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai RN; Saba NF; Shin DM; Owonlkoko TK; Khuri FR
Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions.
Volume: 32
05/20/2014 Authors: Behera M; Steuer CE; Kim S; Pillai RN; Chen Z; Owonikoko TK; Belani CP; Khuri FR; Ramalingam SS
Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A Surveillance, Epidemiology, and End Results database analysis.
Volume: 32
05/20/2014 Authors: Steuer CE; Behera M; Kim S; Chen Z; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy
Volume: 32
05/20/2014 Authors: Behera M; Ragin C; Kim S; Chen Z; Steuer CE; Saba NF; Pillal RN; Belani CP; Ramalingam SS; Khuri FR
Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
Volume: 30
05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L
The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 118 Page(s): 1709 - 1710
11/18/2011 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Langston A; Steuer CE; Flowers CR; Boise LH; Lonial S